Possible role of anti-IL17 drugs in the management of COVID-19: our own experience and literature review
| Autor: | E M Seredenina, A A Kamalov, O. A. Georginova, A. G. Plisyuk, E. A. Shatokhina, T N Krasnova, Ya A Orlova, E P Pavlikova, Valentin Sinitsyn, A. S. Polonskaia, L. S. Kruglova, Elena Mershina |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Immunologiya. 42:243-253 |
| ISSN: | 2412-1312 0206-4952 |
| DOI: | 10.33029/0206-4952-2021-42-3-243-253 |
| Popis: | Coronavirus infection COVID-19 is an acute respiratory viral disease caused by a novel beta-coronavirus SARS-CoV-2. In 81 % of cases, mortality in COVID-19 patients is associated with the development of acute respiratory distress syndrome (ARDS). Another critical challenge associated with COVID-19 is the development of a cytokine storm, which is an uncontrolled release of proinflammatory mediators due to the excessive activation of immune system. Cytokine storm is another cause of high mortality because of COVID-19, as it leads to multiple organ failure, ARDS and disseminated intravascular coagulation (DIC). Thus, the management of cytokine storm and ARDS in COVID-19 patients is an urgent issue for the medical society. Recent research assessed the potential role of interleukin(IL)-17 in the pathogenesis of cytokine storm and ARDS in COVID-19 patients. Some authors also pointed to using anti-IL17 medications in the management of patients with severe COVID-19. The present article gives a literature review on the possible role of IL-17 in COVID-19 pathogenesis and our personal experience of anti-IL17 prescription for patients with severe course of COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|